Cambiar Investors LLC Has $9.36 Million Position in Waters Corporation $WAT

Key Points

• Cambiar Investors LLC has reduced its holdings in Waters Corporation by 18.5%, selling 5,761 shares and now holding 25,407 shares valued at approximately $9.36 million.
• Institutional ownership of Waters Corporation is significant, with 94.01% of stock owned by institutional investors, including notable increases from GAMMA Investing LLC by over 50,000%.
• Waters Corporation reported a quarterly EPS of $2.95, beating estimates, and an 8.8% increase in revenue year-over-year, totaling $771.33 million.

Cambiar Investors LLC lowered its holdings in Waters Corporation (NYSE:WAT - Free Report) by 18.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,407 shares of the medical instruments supplier's stock after selling 5,761 shares during the quarter. Cambiar Investors LLC's holdings in Waters were worth $9,364,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in WAT. GAMMA Investing LLC boosted its position in Waters by 50,228.3% in the first quarter. GAMMA Investing LLC now owns 662,320 shares of the medical instruments supplier's stock valued at $244,111,000 after buying an additional 661,004 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in Waters by 676.8% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 705,733 shares of the medical instruments supplier's stock valued at $260,112,000 after buying an additional 614,877 shares during the period. Millennium Management LLC lifted its holdings in Waters by 3,349.7% in the fourth quarter. Millennium Management LLC now owns 304,404 shares of the medical instruments supplier's stock valued at $112,928,000 after buying an additional 295,580 shares during the period. Nuveen LLC acquired a new position in Waters in the first quarter valued at approximately $94,028,000. Finally, Vanguard Group Inc. increased its stake in Waters by 2.4% in the first quarter. Vanguard Group Inc. now owns 7,272,252 shares of the medical instruments supplier's stock valued at $2,680,334,000 after purchasing an additional 173,584 shares in the last quarter. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on WAT. Robert W. Baird lowered their target price on shares of Waters from $374.00 to $352.00 and set an "outperform" rating for the company in a research note on Wednesday, July 16th. Jefferies Financial Group set a $385.00 target price on shares of Waters and gave the company a "buy" rating in a research report on Monday, August 4th. UBS Group reaffirmed a "neutral" rating on shares of Waters in a research report on Tuesday, July 15th. Wall Street Zen cut shares of Waters from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. Finally, Bank of America increased their price target on shares of Waters from $370.00 to $375.00 and gave the company a "neutral" rating in a research note on Thursday, June 26th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $378.73.

Waters Price Performance

Shares of Waters stock traded down $1.0590 during midday trading on Wednesday, hitting $296.6610. 565,645 shares of the company traded hands, compared to its average volume of 616,302. The stock has a market cap of $17.66 billion, a price-to-earnings ratio of 26.75, a PEG ratio of 2.70 and a beta of 1.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.22 and a current ratio of 1.75. The firm's fifty day moving average price is $317.22 and its 200-day moving average price is $344.47. Waters Corporation has a 12 month low of $275.05 and a 12 month high of $423.56.

Waters (NYSE:WAT - Get Free Report) last posted its earnings results on Monday, August 4th. The medical instruments supplier reported $2.95 EPS for the quarter, topping the consensus estimate of $2.93 by $0.02. Waters had a net margin of 21.71% and a return on equity of 38.60%. The business had revenue of $771.33 million for the quarter, compared to the consensus estimate of $745.96 million. During the same period last year, the company earned $2.63 EPS. The firm's revenue was up 8.8% compared to the same quarter last year. Waters has set its Q3 2025 guidance at 3.150-3.250 EPS. FY 2025 guidance at 12.950-13.050 EPS. As a group, sell-side analysts forecast that Waters Corporation will post 12.86 earnings per share for the current year.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.